Well-differentiated leiomyosarcoma show morphologically recognizable smooth muscle differentiation, while poorly differentiated tumors may form a spectrum with a subset of undifferentiated pleomorphic sarcomas. Expression of certain muscle markers has been reported to have prognostic impact. We investigated the correlation between morphologic spectrum and muscle-marker expression profile of leiomyosarcoma and the impact of these factors on patient outcomes.
Introduction
Leiomyosarcomas account for up to 20% of all adult soft tissue sarcomas, [1] [2] [3] [4] [5] [6] [7] and are characterized by an aggressive clinical course and relative insensitivity to cytotoxic chemotherapy. 4, 5 Leiomyosarcomas demonstrate smooth muscle differentiation, and are typically subclassified for diagnostic and therapeutic purposes as uterine and non-uterine (somatic) origin. Uterine leiomyosarcoma is distinguished from the more common myometrial leiomyomas, by a combination of mitotic activity at least 5/10 high power fields in the presence of necrosis and cellular atypia, or mitotic activity >10/10 high power fields in the absence of necrosis or atypia. [8] [9] [10] [11] In somatic tissues outside of the dermis or gastrointestinal tract, leiomyomas are extremely rare. Thus, smooth muscle tumors with any mitotic activity are generally considered to be leiomyosarcoma, and commonly graded using the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) criteria. 6 Well-differentiated leiomyosarcomas demonstrate a growth pattern of perpendicularlyintersecting cellular fascicles composed of elongated spindle-shaped tumor cells with abundant, brightly eosinophilic, fibrillary cytoplasm. Nuclei generally have an elongated, blunt-ended oval
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"cigar-like" shape. Variable numbers of markedly pleomorphic "monster" cells may be seen. In poorly differentiated tumors, classic features may be focal or difficult to appreciate as the proportion of pleomorphic cells increases. Additional morphologic variants include epithelioid and myxoid types, which are more commonly associated with uterine origin. While the majority of cases can be diagnosed on biopsy based on classic histologic features on H&E stained sections, morphologic variants, poorly differentiated tumors, and those with unusual features may be difficult to distinguish from other sarcomas and may require additional immunohistochemical evaluation. In anaplastic variants, or extremely poorly differentiated tumors, myogenic markers may be lost. 12 Commonly used markers of muscle differentiation in clinical practice include desmin, seen in all types of muscle, smooth muscle actin (SMA), most commonly present in smooth muscle or myofibroblasts, h-caldesmon and smooth muscle myosin (SMMS), both of which are relatively specific for smooth muscle. More recently, expression profiling studies identified an additional set of muscle markers, including smooth muscle gamma actin (ACTG2, typically expressed in enteric smooth muscle), calsequestrin 2 (CASQ2, cardiac and skeletal muscle), human muscle cofilin 2 (CFL2, skeletal muscle), myosin light chain kinase (MYLK, smooth muscle) and sarcolemmal membrane associated protein (SLMAP, all muscle types) as being associated with improved outcomes when 3 or more were co-expressed -so called "muscleenriched" leiomyosarcomas. 13 Few studies have investigated the utility of muscle marker expression as a more objective measure of differentiation status compared to histologic appearance on H&E sections. We therefore queried how well muscle marker expression correlated with histologic assessment of
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Materials and Methods

Patents and tumor tissues
Acquisition of tissue specimens and clinical information and subsequent analyses were approved by the Institutional Review Board (IRB) of The University of Texas M. D. Anderson Cancer Center (UTMDACC).
Tissue microarray construction.
All available formalin-fixed, paraffin-embedded leiomyosarcoma specimens collected between 1993 and 2010 were retrieved from UTMDACC pathology archives. Hematoxylin and eosin (H&E)-stained sections were reviewed to confirm the diagnosis, define areas of viable tumor, and select one or more areas (if there was morphologic variability) for inclusion in tissue microarrays. Extremely poorly differentiated tumors or those that had heterologous elements were only included in the study if they had a prior documented history leiomyosarcoma with at least focal typical immunohistochemical and/or morphologic features.
An automated tissue microarray apparatus (ATA-27, Beecher Instruments, Sun Prairie, WI) was used to obtain and format paired 1.2 mm punch samples from each case into recipient blocks. 14 H&E staining of 4 μm tissue microarray sections was used to verify all samples.
Individual cores on the tissue microarray were screened by an experienced soft tissue pathologist and classified by differentiation score as 1) well, 2) moderately or 3) poorly differentiated ( Figure 1 ). 6 Tumors with myxoid or epithelioid morphology were considered to be moderately
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Clinicopathologic Data Collection
Patient and tumor variables, including age, gender, tumor site, size, and disease status were recorded. Sites of primary tumors were categorized thusly: uterine; vascular (apparently arising from or extensively invading a large caliber vein); retroperitoneal/pelvic (not clearly arising in association with a specific intra-abdominal organ or vascular structure); extremity (leg or arm, including dermal tumors); trunk (chest wall, superficial abdominal wall, back, paraspinal); uterine; or other miscellaneous sites (including viscera, bone and head and neck).
Outcome data including survival and disease recurrence were tabulated for primary tumors only. Complete FNCLCC grading criteria (mitotic figures / 10 high power fields, percent necrosis) were not tabulated because these were not equivalently applicable in primary uterine leiomyosarcoma.
Immunohistochemical analysis
Immunohistochemical staining was performed on 4-μm-thick tissue microarray sections using an automated stainer (Dako, Carpinteria, CA) following the manufacturer's instructions, and commercially available antibodies ( Table 1 ). Positive and negative controls were run in parallel. Sections were counterstained with hematoxylin. SMA, desmin, SMMS, and hcaldesmon were scored as absent (0), focal (<10%) or diffuse (>10%). ACTG2, CASQ2, CFL2, MYLK and SLMAP were scored as completely absent (0), or by intensity if any staining present as weak (1) or strong (2) . For the purposes of outcome analysis, only diffuse/strong staining was
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Statistical methods
Associations between histopathological features and immunophenotype were examined using Fisher's exact test or χ 2 test, with an alpha of p<0.05 (adjusted to p<0.025 for multiple comparisons) considered significant. For primary tumors only, the method of Kaplan and Meier was used to assess outcomes. Univariable and multivariable Cox proportional hazards regression models were used to estimate the association between histopathologic features or biomarker expression with overall survival (OS), disease-specific survival (DSS) and time to first metastasis, with alpha of 0.05 considered as significant.
Results
Leiomyosarcoma characteristics
Tumors included 384 leiomyosarcoma from 257 patients, including 198 women and 59 men. Primary sites of origin included the uterus (41%), retroperitoneum/pelvis (19%), large vessels (16%), extremities (11%), trunk (3%), and miscellaneous sites (9%). Vascular leiomyosarcoma predominately arose in the inferior vena cava and renal vessels, with a few cases originating from other deep veins. Tumors in the head and neck arose in the nasal cavity, sinuses and mandible, while organs giving rise to leiomyosarcoma included lung/bronchus, bowel, bladder, liver and penis. Extremity tumors included 4 leiomyosarcomas of dermal origin.
There were 98 primary leiomyosarcomas, 93 local recurrences (including both those recurring
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When tumors were classified by their microarray core with the least-differentiated histology, there were 130 (34%) well-differentiated leiomyosarcomas, 170 (45%) moderately differentiated and 82 (21%) poorly differentiated. Loss of differentiation correlated with disease progression (p<0.0001), with primary tumors being more frequently well differentiated (53%) than either recurrent (30%, p=0.0013) or metastatic tumors (26%, p<0.0001) ( Figure 2 ). There was no significant further loss of differentiation between recurrent and metastatic tumors.
Muscle marker expression
Smooth muscle markers SMA and ACTG2 were the most frequently expressed (91% and 90% of cases, respectively), while striated muscle marker CASQ2 was least prevalent (18% of cases) ( Table 2 ). In sum, 235/377 (62%) tumors expressed all 4 conventional muscle markers, and 292 (77%) expressed 3 or more, while 56 (15%) expressed only one or no markers. Similarly, muscle-enriched phenotype was seen in 298/357 cases (83%).
Expression of muscle markers correlated with morphologic differentiation (Figure 3 
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2 known risk factors (tumor size, differentiation score) and 2 muscle markers (desmin and CFL2)
were included in the model. All 4 retained independent prognostic significance.
Significant prognostic biomarkers for DSS were similar to those of overall survival ( Table 4) 
Discussion
Although immunohistochemistry is frequently used to support a diagnosis of leiomyosarcoma, few studies have specifically addressed the correlation between morphologic evidence of smooth muscle differentiation and immunohistochemical markers. We examined muscle marker expression in a diverse array of leiomyosarcomas to better understand the patterns of marker loss over the course of disease progression (from well-to poorly differentiated tumors, and from primary to metastatic disease). Of particular interest was whether immunohistochemical markers of muscle differentiation could provide a more objective measure of tumor differentiation than morphology in predicting patient outcomes.
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When we reviewed the leiomyosarcoma tissue cored on our tissue microarray, we identified a number of poorly differentiated cores which showed few, if any, classic features of leiomyosarcoma and which could easily have been mistaken for undifferentiated pleomorphic sarcoma if examined out of context. These cores demonstrated a significant loss of markers of smooth muscle differentiation compared to well and moderately differentiated cores. While Carvalho et al., reported no correlation of muscle marker expression (SMA, desmin, caldesmon, calponin, and myosin) with histologic differentiation in a series of 78 cases, 15 other studies report similar finding as ours, including retention of diffuse SMA in poorly differentiated tumors, with loss of both desmin and caldesmon (59% vs. 83% and 19% vs. 68%, respectively), compared with well-to-moderately differentiated tumors, [16] [17] [18] and loss of smooth muscle marker expression in the less-differentiated areas of pleomorphic and "dedifferentiated" variants of leiomyosarcoma. 12, 19, 20 Not only were individual muscle markers frequently lost in poorly differentiated tumors in our series, but the overall total number of muscle markers was reduced, with less than half of poorly differentiated tumors expressing 3 or more of SMA, desmin, h-caldesmon and SMMS, compared to over 90% of well differentiated tumors. This is consistent with reports that myosin and caldesmon expression are frequently co-expressed. 15 Similarly to Mills et al., 21 we found that poorly differentiated "undifferentiated pleomorphic sarcoma-like" leiomyosarcoma less frequently expressed a muscle-enriched phenotype-that is, positivity for 3 or more of CASQ2, SLMAP, CFL2, MYLK, and ACTG2, with only 62% of poorly differentiated tumors falling into this category, compared to 98% of well-differentiated.
A significant proportion of so-called undifferentiated pleomorphic sarcomas (UPS, formerly termed malignant fibrous histiocytoma) are likely related to leiomyosarcoma and
This article is protected by copyright. All rights reserved. indeed may represent anaplastic ("dedifferentiated") leiomyosarcoma. In multiple studies using protein expression analyses, [22] [23] [24] [25] [26] gene expression analysis [27] [28] [29] [30] and/or comparative genomic hybridization, 31 a subset of UPS consistently cluster with leiomyosarcoma, while up to 5% of UPS demonstrate a muscle enriched phenotype. 21 These studies suggest that a subset of UPS represent a form of tumor progression from leiomyosarcoma. 26, 27, 31, 32 Effectively differentiating between the two classes may have implications for prognostication and therapeutic selection as we more fully understand disease biology.
In our series, desmin and CFL2 were associated with improved OS independent of histologic differentiation or tumor size. Further analysis of desmin expression demonstrated that the impact of this marker in predicting outcome appeared to rest mainly in its ability to segregate moderately differentiated tumors into 2 groups-those that behaved like well-differentiated tumors and those which behaved like poorly differentiated tumors (Figure 4c and d) . We also confirmed, in univariate analyses, the reported association of muscle-enriched phenotype with improved outcome. Of note, our study was underpowered for robust analysis of DSS, due to limited available clinical follow-up. However, in general, prognosticators of OS trended to predict DSS, implying that tumor-related deaths may have been more frequent in our cohort than we were able to confirm.
While we found that increased muscle marker expression predicted improved outcomes in leiomyosarcomas, other studies have found that UPS expressing muscle markers behave more aggressively than those without. 22, [33] [34] [35] Thus, we are left with the seeming paradox that evidence of myoid differentiation is a positive predictor in leiomyosarcomas, and negative one in true UPS.
This contradiction merits further study and reinforces the need to carefully evaluate biomarkers only in context with morphology.
In summary, we assessed the diagnostic and prognostic utility of an array of muscle markers in one of the largest cohorts of uterine and non-uterine leiomyosarcoma to date. We demonstrated that morphologically less-well-differentiated leiomyosarcoma are associated with loss of markers of muscle differentiation, thereby reducing the diagnostic value of immunohistochemistry in biopsies of such cases. Moreover, our findings are congruent with the theory that a subset of UPS represent pleomorphic or very poorly differentiated variants of leiomyosarcoma. Lastly, we identified desmin as an independent predictor of survival, which seems to be of most value in moderately differentiated tumors. Taken together our findings help to more clearly delineate patterns of muscle expression in leiomyosarcoma, which may help to improve diagnostic algorithms, and provide evidence for overlooked prognostic significance of everyday immunohistochemical assays. 
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This article is protected by copyright. All rights reserved. Tumor status correlates with differentiation. Primary tumors are most frequently welldifferentiated (53%) compared to recurrence or metastases (30%, p=0.0013 and 26%, p<0.0001 respectively). Poorly differentiated tumors are most commonly metastases (29%) compared to 19% recurrences (p=0.087), and 9% of primaries (p=0.0001).
Figure 3. Expression of Markers of Smooth Muscle Differentiation in Leiomyosarcoma
